Hemedex, Inc. Hosts First Annual Tissue Perfusion Symposium
CAMBRIDGE, Mass.--(BW Health Wire)--June 5, 2001--Hemedex, Inc., a privately held company developing a stream of products to provide valuable new prognostic data by measuring tissue blood flow for multiple clinical application areas, today announced details from the Company's First Annual Tissue Perfusion Symposium, which was held at the Boston Cambridge Marriott Hotel in Kendall Square on May 18th-19th.
At the Symposium, eight of the Company's clinical investigators from around the world presented data from their clinical trials to an audience of 65 clinicians, healthcare industry executives, biomedical scientists and engineers, for analysis and discussion.
Data from both pre-clinical and clinical applications of the Company's proprietary thermal diffusion technology, which is used to quantify real time blood flow in absolute units in small volumes of tissue (i.e., measure "Perfusion") was presented from areas such as organ transplantation, neurosurgery, plastic/reconstructive surgery and shock monitoring, among others. Prior to the development of this technology, the capability to get continuous, real time perfusion measurements in absolute units did not exist. The measurements made by the Company's technology are a long sought after and important parameter in understanding and managing critical medical situations. In addition, the Hemedex 2001 Distinguished Investigator Award was presented to Ernst Klar, M.D., Vice Chief of Surgical Services and Chief of Transplantation Surgery at the University of Heidelberg, Germany, whose work with the Company's technology produced 92% positive predictive data of impending liver transplant failure in 72 cases. This is significant in that the technology provides surgeons an early warning of impending organ failure, which allows for proactive management of the case to correct the problem. Dr Klar was honored for his pioneering work in using the Company's technology to advance evidence-based medicine in organ transplantation indications. Also, Peter Vajkoczy, M.D., from the Department of Neurosurgery at the University of Heidelberg presented his work, which validated the capability to measure absolute cerebral perfusion accurately and in real time, and was awarded the Company's Pioneer Investigator Award. This honor was in recognition of Dr. Vajkoczy's successful work in identifying significant clinical applications for the Company's perfusion monitoring technology in neurosurgical indications. His results have been published in the prestigious Journal of Neurosurgery (August 2000) and in Stroke (February 2001).
Dr. H. Frederick Bowman, Chairman of Hemedex, commented, "We are delighted to present the positive and accurate data from using our perfusion monitoring technology in a broad array of medical and surgical disciplines, and we are very gratified at the keen interest and understanding of its potential that was shown by the attending clinicians and healthcare executives".
About Hemedex, Inc. -
Hemedex, Inc., located in Cambridge, Massachusetts, is a vertically integrated medical device company that designs, develops and markets minimally invasive, perfusion-measuring devices that address critical medical problems in areas that include neurosurgical monitoring, organ transplantation, cardiovascular monitoring, reconstructive surgery and oncology. Hemedex plans to further apply its proprietary techniques and expertise in thermal physics, instrumentation and biomedical engineering to other clinical application areas where it can provide a powerful new tool for physicians and have a significant impact on the progress of patient monitoring and therapy. Hemedex's products are based on a proprietary, platform perfusion quantification technology, licensed from Thermal Technologies, Inc. of Cambridge, MA, which was originally developed at the Massachusetts Institute of Technology with funding from the National Institute of Health.
[ TOP ]